SCHEMBL165664

SCHEMBL165664

Cn1cc(-c2cc(C(=O)O)c(OCc3ccccc3)cc2C(=O)N2CCOCC2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.49
NMT2 O60551 1/20 0.48
NMT1 P30419 1/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 3/20 0.46
LRRK2 Q5S007 2/20 0.45
NPSR1 Q6W5P4 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
APP P05067 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
AXL P30530 2/20 0.42
MERTK Q12866 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165531 0.92 LRRK2 (0.46) HSD17B10NMT2NMT1KDM4EHPGD
SCHEMBL169086 0.91 LRRK2 (0.47) NMT1HPGDMAPTALDH1A1LRRK2
SCHEMBL257185 0.86 LRRK2 (0.61) LRRK2CYP3A4SLCO1B1
SCHEMBL256246 0.86 LRRK2 (0.67) LRRK2CYP3A4SLCO1B1
SCHEMBL257050 0.86 LRRK2 (0.51) HSD17B10NMT2NMT1LRRK2CYP3A4
SCHEMBL256260 0.86 LRRK2 (0.46) HSD17B10NMT2NMT1KDM4EHPGD
SCHEMBL165393 0.83 MEN1 (0.46) NMT1HPGDLMNAMAPTALDH1A1
SCHEMBL168617 0.82 LRRK2 (0.49) LRRK2AXLMERTKFGFR1FGFR3
SCHEMBL15204962 0.81 LRRK2 (0.55) MAPTLRRK2MEN1KMT2ANPC1
SCHEMBL10193684 0.80 LRRK2 (0.58) LRRK2CYP3A4SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 HSD17B10 2900/4885NMT2 1096/4885NMT1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.